Overview
Ceylon Hospitals operates the Durdans hospital, an islandwide diagnostics and laboratory network, and supporting healthcare education and biotechnology businesses. The latest earnings record shows a profitable group with strong annual growth, but the most recent quarter points to pressure below the revenue line and weaker operating leverage.
Price performance
The price sits at 47.0% of its 52-week range, or 31.6% below the high and 69.1% above the low. Recent volatility was 43.6% below its own one-year level, while 20-day volume was 3.2% below its 60-day average, indicating quieter trading rather than a broad-based loss of interest.
Valuation
The dividend yield is 1.7%. The payout has increased from LKR 1.0 per share in FY2025 to LKR 1.1 in FY2026, following LKR 0.5 in FY2024, so the recent direction is upward even though the yield remains below the sector median.
News and sentiment
Direct coverage is thin: only one material company article appeared in the 90-day window, and it was positive. The article reported the LKR 1.1 first interim dividend, which went ex on 2026-06-01 and was payable on 2026-06-18. The 1:4 share subdivision also went ex on 2026-03-05.
Financials
The twelve months to 2026-06-30 produced revenue of LKR 11.21 billion, up 9.3%, while the audited year ended 2026-03-31 recorded revenue growth of 12.6% and net-profit growth of 44.9%. Equity attributable to owners reached LKR 11.99 billion, and the share count was 167.59 million after the 1:4 subdivision on 2026-03-05. Per-share comparisons around the action are therefore mechanical and should not be read as operating trends.
Risks
The balance sheet is not highly leveraged, with gearing at 11.2% of owners' equity and interest cover of 8.07 times at 2026-03-31. Liquidity was adequate at a 1.47 current ratio, but 9.6% of annual group profit belonged to minority shareholders, meaning group net profit is not identical to the earnings attributable to the shares being valued. Healthcare operators also face governance and cybersecurity exposure, while the sector's pharmaceutical policy initiatives have not yet produced a reported material operating change.
Outlook
Easier interest-rate conditions in Sri Lanka could reduce financing pressure across healthcare operators, but the company-specific data cannot establish how much of any future earnings change would come from operating performance, finance costs or other below-the-line items. With limited direct news coverage, the next filing carries greater informational weight.